NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Frequently asked questions
What sector does NervGen Pharma Corp. (NGEN) operate in?
NervGen Pharma Corp. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is NervGen Pharma Corp. (NGEN) current stock price?
As of the latest data, NervGen Pharma Corp. stock price is $1.42, with a previous close of $1.43. NervGen Pharma Corp. lost -$0.01 in the last trading session, representing a -0.7% loss.
What is NervGen Pharma Corp. (NGEN) current market capitalization?
NervGen Pharma Corp. market cap is approximately 152.68 million.
What is NervGen Pharma Corp. (NGEN) Earnings Per Share (EPS)?
The trailing EPS is -$0.56, and the forward EPS is -$0.34.
What is NervGen Pharma Corp. (NGEN) EBITDA?
NervGen Pharma Corp. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -8.81 million.
Does NervGen Pharma Corp. (NGEN) pay dividends?
No. NervGen Pharma Corp. does not pay a dividend.
When is NervGen Pharma Corp. (NGEN) next earnings report?
NervGen Pharma Corp. is expected to release its next earnings report on September 30, 2026.
What is NervGen Pharma Corp. (NGEN) beta (volatility) score?
NervGen Pharma Corp. has a beta of 0.730, indicating lower volatility than the overall market.
